AKAnna Kjær Kristensen

Anna Kjær Kristensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Kjær Kristensen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fertility treatment and risk of non-Hodgkin lymphoma – results from a Danish population-based cohort study

    by Anna Kjær Kristensen, Clarissa Lima Brown Frandsen, Maria Møller, Bugge Nøhr, Henrik Hjalgrim, Jakob Hansen Viuff, Marie Hargreave, Susanne Krüger Kjær, Allan Jensen

    Purpose To investigate the association between fertility drug use and non-Hodgkin lymphoma. Methods This cohort study utilized data from the extensive Danish Infertility Cohort, comprising 148,036 women with fertility problems residing in Denmark between January 1, 1995 and December 31, 2017. The study cohort was linked to national registers to gather information on fertility drug use, cancer diagnoses, covariates, and emigration and vital status. Cox proportional hazard models were employed to calculate hazard ratios (HRs) and 95% confidence intervals for non-Hodgkin lymphoma (overall and for histologic subtypes), with adjustments for potential confounders. Results Over a median follow-up of 11.3 years, 115 women were diagnosed with non-Hodgkin lymphoma. After adjustment for potential confounders, overall non-Hodgkin lymphoma rates were decreased following treatment with all specific types of fertility drugs analyzed being clomiphene citrate (HR 0.74; 95% CI 0.43–1.26), gonadotropins (HR 0.67; 95% CI 0.39–1.16), hCG (HR 0.69; 95% CI 0.41–1.17), GnRH receptor modulators (HR 0.58; 95% CI 0.33–1.03), and progesterone (HR 0.69; 95% CI 0.39–1.21). However, none of these associations were statistically significant implying that the results should be interpreted with great caution. Similar trends were seen for B-cell lymphomas. For most fertility drugs, we observed a tendency toward lower associations within the first 10 years after start of drug use. Conclusion The findings of this study do not indicate any strong associations between the use of fertility drugs and the risk of non-Hodgkin lymphoma. However, the relatively young age of the cohort at the end of follow-up underscores the need for an extended follow-up period to evaluate the long-term risk of non-Hodgkin lymphoma in women who have used fertility drugs.

  • Open Access

    Major cardiovascular events in patients with severe COPD with and without asthma: a nationwide cohort study

    by Barbara Bonnesen, Pradeesh Sivapalan, Anna Kjær Kristensen, Mats Christian Højbjerg Lassen, Kristoffer Grundtvig Skaarup, Ema Rastoder, Rikke Sørensen, Josefin Eklöf, Tor Biering-Sørensen, Jens-Ulrik Stæhr Jensen

    Background: Chronic low-grade inflammation as in asthma may lead to a higher risk of cardiovascular events. We evaluated whether patients with COPD and asthma have a higher risk of acute cardiovascular events than patients with COPD without asthma.Methods: Nationwide multicentre retrospective cohort study of Danish outpatients with a specialist diagnosis of COPD with or without asthma. Patients with both COPD and asthma were propensity-score matched 1:2 to patients with COPD without asthma. The primary end-point was severe major adverse cardiac events (MACE), defined as mortal cardiovascular events and events requiring revascularisation or hospitalisation.Results: A total of 52 386 Danish patients with COPD were included; 34.7% had pre-existing cardiovascular disease, and 20.1% had asthma in addition to their COPD. Patients with pre-existing cardiovascular disease were then propensity-score matched: 3690 patients with COPD and asthmaversus7236 patients with COPD without asthma, and similarly, for patients without pre-existing cardiovascular disease (6775 matched with 13 205). The risk of MACE was higher among patients with asthma and COPDversusCOPD without asthma: hazard ratio (HR) 1.25 (95% CI 1.13–1.39, p<0.0001) for patients with pre-existing cardiovascular disease and HR 1.22 (95% CI 1.06–1.41, p=0.005) for patients without pre-existing cardiovascular disease.Conclusion: Among patients with COPD, asthma as a comorbid condition is associated with substantially increased risk of cardiovascular events. The signal was an increased risk of 20–25%. Based on our study and other smaller studies, asthma can be considered a risk factor for cardiovascular events among COPD patients.


  • Open Access

    Association between anticoagulant therapy, exacerbations and mortality in a Danish cohort of patients with Chronic Obstructive Pulmonary Disease

    by A Kristensen, P Sivapalan, K Bagge, T Biering-Sørensen, R Sørensen, J Eklöf, Jus Jensen

    Objectives: Pulmonary Embolism has been frequently reported in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD). The study aimed to determine whether COPD patients who receive anticoagulant (AC) therapy have a reduced risk of hospitalization due to AE-COPD and death. Methods: This nationwide population-based study was based on data from the Danish Register of COPD (DrCOPD), which contains complete data on COPD outpatients between 1st January 2010 and 31st December 2018. National registers were used to obtain information regarding comorbidities and vital status. Propensity-score matching and Cox proportional hazards models were used to assess AE-COPD and death after one year. Results: The study cohort consisted of 58,067 patients with COPD. Of these, 5194 patients were on AC therapy. The population was matched 1:1 based on clinical confounders and AC therapy, resulting in two groups of 5180 patients. We found no association between AC therapy and AE-COPD or all-cause mortality in the propensity-score matched population (HR 1.03, 95% CI 0.96-1.10, p = 0.37). These findings were confirmed in a competing risk analysis. In the sensitivity analysis, we performed an adjusted analysis of the complete cohort and found a slightly increased risk of AE-COPD or death in patients treated with AC therapy. This study found a low incidence of pulmonary embolisms and deep venous thrombosis in both groups. Conclusions: AC therapy was not associated with the risk of hospitalization due to AE-COPD or all-cause mortality.